- NCIt
- C8101
Loading cancer entity…
Loading cancer entity…
Clinical trials
1,164 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05284214 | Sargramostim With Ipilimumab Containing Therapy in Patients With Solid Tumors(SALIENT) | withdrawn | Phase 2 | 0 | Partner Therapeutics, Inc.INDUSTRY | 1 | Sep 15, 2023 | clinicaltrials |
| NCT04315246 | 177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma) | withdrawn | Phase 1 / Phase 2 | 0 | Y-mAbs TherapeuticsINDUSTRY | 2 | Jul 15, 2022 |
| NCT01644097 | Probiotic Supplementation in Preventing Treatment-Related Diarrhea in Patients With Cancer Undergoing Chemotherapy | withdrawn | Phase 2 | 0 | Stanford UniversityOTHER | 1 | Feb 14, 2014 | clinicaltrials |
| NCT01101412 | Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With Malignancies | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Feb 15, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Sep 15, 2023source: clinicaltrials